GlaxoSmithKline plc or AstraZeneca plc? Which Drugs Giant Should You Buy?

Bilaal Mohamed analyses the investment potential of GlaxoSmithKline plc (LON: GSK) & AstraZeneca plc (LON: AZN). Which giant will best help your portfolio hit the big time?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When it comes to ‘Big Pharma’, they don’t come any bigger than GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) – well in the UK at least. Valued at around £68bn and £50bn, respectively, they’re both more than twice the size of the only other FTSE 100 listed pharmaceutical company Shire plc (LSE: SHP). So which is the best investment?

Joint venture boost

GlaxoSmithKline is one of the world’s leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000 to create one of the UK’s largest listed companies, and the country’s most gigantic drugs giant.

Glaxo’s full year results announced last month revealed an increase in revenues to £24bn, up from £23bn, and a sharp rise in pre-tax profits to £10.5bn, up from £3bn the previous year. This was mainly due to its deal with Swiss pharmaceutical giant Novartis, where Glaxo sold cancer drugs, acquired a vaccines business and set up a joint venture in consumer healthcare.

The outlook for the firm looks good, with our friends in the City expecting earnings to rise by 13% this year, followed by a further improvement of 6% earmarked for 2017. Dividends are forecast at 82.03p per share for this year, falling slightly to 80.36p next year, offering prospective yields of 5.9% and 5.8% for the next two years.

Glaxo trades on 16 times forecast earnings for this year, falling to 15 for the year ending 31 December 2017. That may not make them a bargain but the shares look fairly priced given the earnings outlook, while the strong dividend and defensive qualities should tempt income investors.

Losing its patents

AstraZeneca is another leading pharmaceuticals group created by a merger, in this case the 1999 merger of Sweden’s Astra and the UK’s Zeneca, which had itself been de-merged from chemicals group ICI in 1993.

Astra has its problems. Announcing its annual results last month, the company reported a 7% drop in revenues to $24.7bn as sales of its major drugs slowed due to generic competition. And while pre-tax profits were up from $1.2bn to $3bn, this was mostly as a result of cost-cutting.

Astra faces a tough year ahead too with the patent for its most important drug, the anti-cholesterol statin Crestor, expiring in May. Consequently, analysts in the Square Mile expect earnings to be 5% lower this year, with a further 1% decline pencilled-in for 2017. But dividends are forecast at 193.59p per share for this year, rising slightly to 194.15p next year, offering prospective yields of 5% for the next couple of years.

AstraZeneca trades on 14 times forecast earnings for this year, rising slightly to 14.1 for the year ending 31 December 2017. The firm’s P/E rating is moderate and on a par with GlaxoSmithKline, but the shares offer a strong dividend that should be attractive to income hunters, despite the firm’s challenges.

What next?

In my opinion Glaxo edges past Astra given the stronger earnings outlook and slightly higher dividend yield. So which should you buy?  How about both? Each continues to offer strong defensive qualities and healthy income, which is why many UK-based portfolios have either or both of these pharmaceutical giants as core holdings.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »